Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for men with castration-resistant prostate cancer (CRPC). However, not all patients respond, and resistance mechanisms are largely unknown. We hypothesized that genomic and transcriptional features from metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Alumkal, Joshi J., Sun, Duanchen, Lu, Eric, Beer, Tomasz M., Thomas, George V., Latour, Emile, Aggarwal, Rahul, Cetnar, Jeremy, Ryan, Charles J., Tabatabaei, Shaadi, Bailey, Shawna, Turina, Claire B., Quigley, David A., Guan, Xiangnan, Foye, Adam, Youngren, Jack F., Urrutia, Joshua, Huang, Jiaoti, Weinstein, Alana S., Friedl, Verena, Rettig, Matthew, Reiter, Robert E., Spratt, Daniel E., Gleave, Martin, Evans, Christopher P., Stuart, Joshua M., Chen, Yiyi, Feng, Felix Y., Small, Eric J., Witte, Owen N., Xia, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2020
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275746/
https://www.ncbi.nlm.nih.gov/pubmed/32424106
http://dx.doi.org/10.1073/pnas.1922207117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275746/
https://www.ncbi.nlm.nih.gov/pubmed/32424106
http://dx.doi.org/10.1073/pnas.1922207117

Ejemplares similares